← Back to Clinical Trials
Recruiting NCT07222475

NCT07222475 Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07222475
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Sickle Cell Disease
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-02-05
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 11 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Songwriting intervention (active music therapy)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-02-05 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research aims to see if songwriting can help reduce anxiety in adolescents with Sickle Cell Disease. The purpose of the study is to discover if participants find songwriting and playing their songs to be practical and acceptable, and helpful for managing anxiety.

Eligibility Criteria

Inclusion Criteria: * Adolescents aged 11-18 years of age at the time of enrollment and able to provide assent * Diagnosed with any type of sickle cell disease * Currently receiving care at pediatric center * Able to read and write in English Exclusion Criteria: * Care transitioned to adult facility * Visual, hearing, or cognitive impairment which may impede the ability to complete the songwriting intervention or data collection measures

Contact & Investigator

Central Contact

Pam Peterson

✉ Peterson.Pamela@Mayo.edu

📞 507-422-5523

Principal Investigator

C. Robert Bennett, PhD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT07222475 clinical trial?

This trial is open to participants of all sexes, aged 11 Years or older, up to 18 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07222475 currently recruiting?

Yes, NCT07222475 is actively recruiting participants. Contact the research team at Peterson.Pamela@Mayo.edu for enrollment information.

Where is the NCT07222475 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT07222475 clinical trial?

NCT07222475 is sponsored by Mayo Clinic. The principal investigator is C. Robert Bennett, PhD at Mayo Clinic. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology